Special Issue "Epigenetics in Cancer"

A special issue of Biomolecules (ISSN 2218-273X).

Deadline for manuscript submissions: 30 June 2020.

Special Issue Editor

Dr. Ryuji Hamamoto
E-Mail Website
Guest Editor
National Cancer Center Research Institute, Tokyo, Japan
Interests: cancer epigenetics; precision medicine; multi-omics analysis

Special Issue Information

Dear Colleagues,

Epigenetics is defined as the heritable modification of gene expression without changing the DNA sequence through processes that involve DNA methylation, chromatin remodelling and expression of regulatory RNAs. Because epigenetic modifications can be altered by external and internal environmental factors and have the ability to change gene expression, epigenetics is now considered to be an important mechanism to maintain homeostasis in the human body. Recently, it was reported that epigenetic deregulation, such as abnormal histone modifications, DNA methylation patterns and non-coding RNA expression levels, plays a critical role in human tumorigenesis. The enzyme group that controls abnormal molecular modification and non-coding RNA is considered to be an important target group for cancer treatment. In addition, advanced technologies, such as ChIP-seq, ATAC-seq, Hi-C, and ChIA-PET, have been used to unveil sophisticated chromatin regulation mechanisms, which may allow us to explore the importance of epigenetics in a systematic manner. With this Special Issue, we aim to clarify the significance of epigenetic deregulation in cancer, in particular using advanced technologies. This Special Issue will include reviews, original research articles and short contributions.

Dr. Ryuji Hamamoto
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • epigenetics
  • histone modifications
  • DNA methylation
  • non-coding RNA
  • omics analysis
  • chromatin structure analysis
  • big data
  • multimodal analysis

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Open AccessArticle
Phylogenetic Analysis to Explore the Association Between Anti-NMDA Receptor Encephalitis and Tumors Based on microRNA Biomarkers
Biomolecules 2019, 9(10), 572; https://doi.org/10.3390/biom9100572 - 05 Oct 2019
Abstract
MicroRNA (miRNA) is a small non-coding RNA that functions in the epigenetics control of gene expression, which can be used as a useful biomarker for diseases. Anti-NMDA receptor (anti-NMDAR) encephalitis is an acute autoimmune disorder. Some patients have been found to have tumors, [...] Read more.
MicroRNA (miRNA) is a small non-coding RNA that functions in the epigenetics control of gene expression, which can be used as a useful biomarker for diseases. Anti-NMDA receptor (anti-NMDAR) encephalitis is an acute autoimmune disorder. Some patients have been found to have tumors, specifically teratomas. This disease occurs more often in females than in males. Most of them have a significant recovery after tumor resection, which shows that the tumor may induce anti-NMDAR encephalitis. In this study, I review microRNA (miRNA) biomarkers that are associated with anti-NMDAR encephalitis and related tumors, respectively. To the best of my knowledge, there has not been any research in the literature investigating the relationship between anti-NMDAR encephalitis and tumors through their miRNA biomarkers. I adopt a phylogenetic analysis to plot the phylogenetic trees of their miRNA biomarkers. From the analyzed results, it may be concluded that (i) there is a relationship between these tumors and anti-NMDAR encephalitis, and (ii) this disease occurs more often in females than in males. This sheds light on this issue through miRNA intervention. Full article
(This article belongs to the Special Issue Epigenetics in Cancer)
Show Figures

Figure 1

Back to TopTop